Pharmacokinetic and Mass Balance Study of Oral-Administrated [14C]-DZD9008 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 24, 2021

Primary Completion Date

March 30, 2022

Study Completion Date

March 30, 2022

Conditions

Healthy Volunteers

Interventions

DRUG

[14C]-DZD9008

Each subject will receive a total of 100 mg DZD9008 oral suspension containing approximately 1 μCi of \[14C\] as a single administration

Trial Locations (1)

Labcorp Clinical Research Unit, Madison site, Madison